Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SEK-1005
- Development stage
- Discontinued
- Modality
- Peptides
- Administration
- Intraperitoneal, Subcutaneous, Topical
01
Overview
SEK-1005 is a novel cyclic peptide originally isolated from Streptomyces nobilis and developed by Sekisui Chemical. It acts as a potent inducer of transforming growth factor-beta 1 (TGF-beta1). SEK-1005 has been investigated for its wound healing acceleration and anti-inflammatory properties, demonstrating effects comparable to basic fibroblast growth factor (bFGF) in wound healing and prednisolone in suppressing inflammation. Additionally, SEK-1005 has been studied in bioengineering applications, such as coating agarose rods or platinum coils, to promote local angiogenesis and vascularization, which can facilitate subcutaneous pancreatic islet transplantation for type 1 diabetes or prevent aneurysm recanalization.
- Other names
- SEK 1005SEK1005SEK-1005
Beyond the preview
Go deeper on SEK-1005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SEK-1005.